source
- Travere Therapeutics pays $112 million upfront to China’s Everest Medicines to expand rare kidney disease pipelineTravere Therapeutics, a San Diego‑based biotech, announced a partnership with China‑based Everest Medicines to strengthen its rare kidney disease portfolio beyond its approved drug Filspari. Under…
- Legend Biotech reports first in vivo CAR-T data from Chinese lymphoma trialLegend Biotech has released its first in vivo CAR-T cell therapy data, marking the next step after its CAR-T product Carvykti. The data come from an investigator-initiated trial in China that enro…